Working capital as survival: eleven years without a safety net

Working capital is a line on a statement until the money funding it is your own. Eleven years running a self-funded consumer brand, its products manufactured under contract in the Far East and sold direct to customers, taught me the disciplines that keep such a business alive, and they translate to a mid-market finance function when the credit line is thinner than the board would like.

The cash conversion cycle with your name on it

Every finance textbook draws the same diagram: cash goes out to buy inventory, inventory sells, receivables convert, cash comes back, and the gap in the middle, net of the terms your suppliers give you, is the working-capital requirement. In a larger business a facility can smooth that gap, and it can also make weaknesses in the cycle easier to tolerate for longer; the cycle becomes a number of days to monitor rather than a fact to survive. Run the same cycle on your own capital, with no facility behind you, and it stops being a number on a report.

For eleven years I have owned that cycle end to end in my own company, a UK consumer brand: my own trademarked products, manufactured under contract in the Far East and sold through Amazon's US, UK and European marketplaces alongside Shopify. Contract manufacturing is the operating model most modern product businesses now run, because carrying the infrastructure cost and complexity of a factory rarely makes sense. Whole industries are built on it: consumer goods, electronics, and the own-label ranges on every retailer's shelf all come out of factories owned by someone other than the brand. And it holds even in pharmaceuticals, among the most regulated manufacturing there is: the share of pharmaceutical production outsourced to contract manufacturers has risen from roughly a third in 2014 to around half by 2023, and most small biotechs never build a plant at all, since a GMP facility runs to hundreds of millions of dollars and years of build time, so they reserve contract capacity instead, on agreements that commonly run five and even ten years. Moderna's manufacturing collaboration with Lonza, signed in 2020, runs ten. The shape of the cycle, at my scale, is unforgiving. A supplier is paid months before a single unit sells, and beyond the terms the factory will agree, no one finances that gap but me. Freight transit and customs clearance add further weeks before a unit can be sold, while the freight and duty themselves add to the cash committed. The stock then sits in a fulfilment centre until demand pulls it through, and only then does the platform settle, on its own schedule. The distance between the day my money left and the day the customer's money became mine to spend was routinely measured in months, and it was funded from cash I already had.

That is the cash conversion cycle with your name on it. There is no revolving facility to postpone the lesson, no treasury desk to draw on, no group balance sheet absorbing the timing. The gap is real money, and it is yours. The stakes are on the public record: of UK businesses started in 2019, the latest cohort with a full five-year record, only 56% reached their third year and fewer than four in ten reached their fifth (ONS Business Demography, published November 2025). What follows are the five disciplines that carried this one solvent through eleven years of that arithmetic, including a category collapse that tested whether those disciplines were real or merely stated.

Five disciplines that keep a self-funded brand alive

Size the buy to the cash, not to the forecast's best case. Every purchase order is a cash bet placed months before the customer decides whether it was a good one. Inventory has to be sized against a demand model and the cash runway together, never against optimism, because dead stock is capital you cannot spend and cannot easily recover. The forecasting rigour matters most precisely here, where the number turns straight into committed cash. I now run that demand and landed-cost model as a living one: built with Claude Code, interrogated through Claude and ChatGPT in Excel, and, on the calls that matter, cross-examined by a panel of independent models before I act, because no preparer, human or machine, should approve their own work. The discipline, though, predates the tools: buy what the demand and the cash both support, and no more.

Treat supplier terms as the only credit line you have. With no bank facility, the factory's payment terms are the working-capital facility, and every day of terms negotiated is a day of your own cash freed. The structure I started with was simple: 30% on order, 70% on completion, cash committed months before a unit could sell. That structure has come under real pressure since, from a run of shocks a plan would once have treated as once-a-generation events: a pandemic, wars, blockages of key shipping straits, tariff disputes layered on top. Fuel and freight costs up, trade routes that used to be reliable now adding weeks, tariffs on landed cost that were not there a few years ago, and every one of those shifts has to be renegotiated into the terms or absorbed into margin.

The renegotiation itself is where the real craft sits, and it works better as a partnership conversation than a demand. Once a supplier trusts the relationship there is a genuine range of structures available: shifting a slice of the balance to 30 days after delivery, or moving the payment trigger from despatch to arrival at the destination port. That second lever matters most for ocean freight, where the sailing itself can run anywhere from 15 to 45 days depending on the lane, so tying payment to arrival rather than to despatch finances the voyage out of the supplier relationship instead of out of my own cash. None of this is a template. What works for one supplier, one product, one shipping lane will not be the right structure for the next, and the discipline is knowing which lever to pull with which supplier rather than applying one policy everywhere.

Supplier payment terms are not procurement details; they are one of the business's principal liquidity levers, not a policy to inherit and leave unquestioned. When the market turned, the first place I went for cash was not a lender, because there was none; it was the supplier relationship, renegotiating terms under pressure because that is where the working capital actually sat.

Price from landed cost, not from invoice cost. Margin is defended at the landed-cost line, not the invoice line. Landed cost starts with unit cost plus freight plus duty, all of it restated through the exchange rate, and each of those components moves on its own clock. A price that looks healthy against the factory invoice can be underwater once the container, the customs bill and a currency move are in it, and a renegotiated factory price only reaches the margin line months later, when the inventory it bought finally sells through. I carry landed cost in the model because the shortfall, if I get it wrong, is mine.

Hold cash for the trough, not the peak. A seasonal business tempts you to spend the peak's cash the moment it arrives. The discipline is the opposite: the peak funds the trough that follows it, and a genuine demand shock funds nothing at all. Capital preservation over growth-at-all-costs is not caution for its own sake. It is a large part of why the business traded through a category collapse of more than seventy per cent, on its own capital, with no facility to draw on, from the collapse to the rebound. A business that had spent its peaks would not have had the trough covered.

Know your counterparty's settlement clock better than your own. The customer's money does not become yours when the sale completes. The platform settles on its own schedule and holds a reserve, so cash-in timing is a variable to be modelled, not assumed. The gap between when the money is earned and when it can be spent is the gap the whole business is funding, and a finance leader who does not know that clock precisely is guessing at the one number that decides whether next month's stock gets bought.

None of these is exotic. They are the working-capital fundamentals every finance course teaches. The difference is that eleven years without a safety net turned them from things I understood into things I live by, because the penalty for getting any one of them wrong was not a variance to explain at the month-end review. It was the business.

None of this is only about survival, either. In a stock-led, cash-out-first business like mine, working capital is also a hard constraint on how fast the business can afford to grow. Growth demands more stock before it delivers more cash: a rising sales trend means the next purchase order has to be bigger before the revenue behind the last one has fully landed, and if the cash conversion cycle cannot fund that step up, growth stalls at exactly the moment it should be accelerating, or it gets funded by stretching supplier terms and drawing down cash reserves further than the business can sustain. A business that cannot answer, at any point on its growth curve, how the next purchase order gets paid for is not ready for the growth it is chasing. That is one end of a spectrum, though, not a universal model.

The opposite structure exists, and some businesses are built on it: the customer's money arrives before the supplier has to be paid at all, so the working-capital element of growth part-funds itself. Dell built exactly this in the 1990s. Selling direct and building to order kept its inventory exceptionally low and let it collect from customers before it had settled its component suppliers, allowing supplier credit to help fund its growth rather than draining cash to feed it. Costco runs a version of the same logic in retail today: inventory turns fast enough that it often sells stock before the supplier bill falls due, giving it a cash conversion cycle that runs close to zero and at times negative, with membership fees sitting alongside that as a separate source of upfront cash. Insurers run the purest version of all, collecting premiums long before claims fall due, and airlines and tour operators bank the customer's cash months before the seat or the holiday is delivered. In models like those, the working-capital element of growth can become partly, and sometimes largely, self-funding. Either way the discipline is the same: know where your own business actually sits on that spectrum, and fund growth accordingly.

What a corporate finance function can copy

The reason this matters beyond my own company is that the same disciplines, unlearned or hidden by a facility, are where mid-market finance functions quietly lose money and momentum. The cash conversion cycle is the same arithmetic at every scale; what changes is whether a credit line is quietly paying for its inefficiencies.

I have run the corporate side of this too. At Parexel I took accounts-receivable days from 65 to 40 during the turnaround, a material improvement to the cash conversion cycle at NASDAQ-listed scale, and it came from the same instinct: cash trapped in the cycle is cash the business already owns and is failing to use. At GSK, currency-level funding forecasts I produced fed into group treasury's decisions on funding needs and the timing of bond raises, cash visibility as an input to real capital decisions rather than a report filed after them. And at Shionogi, as European Financial Controller of a Japanese pharmaceutical group's EMEA hub, I ran the monthly close, forecasting and statutory consolidation across a multi-entity, multi-currency estate: the cash and performance visibility a parent company half a world away depended on, where the numbers had to be right first time.

There is a manufacturing version of the same discipline, and in pharma and most product sectors it quietly decides group margins: factory utilisation aligned to real market demand. A factory is a fixed cost, and the misalignments run in both directions. Under-utilisation leaves that cost unabsorbed across too few units. High utilisation pointed at the wrong products is worse: working capital piles up as stock the market does not want, while the products that are actually growing run under-manufactured and long on lead time. The alignment has to run from the product portfolio, with an honest view of which products deserve capacity at their stage of life, through market demand and its triggers, all the way into the production plan, and finance is the function positioned to hold that line end to end, because it is the only one that sees the margin, the stock and the demand signal in the same set of numbers. I ran the service-industry version of this at Parexel, where clinical site capacity was a bed-based fixed cost and every contract had to be priced against realistic occupancy rather than theoretical capacity, or the overhead of running the site was never recovered.

What a corporate function can copy is the posture, not the panic. None of this is an argument against credit: a facility used deliberately is a rational tool. It must not, though, substitute for knowing the cycle it is funding. Hold the thirteen-week cash view as an instinct, not a monthly artefact produced for a covenant test. Treat receivable days, payable days and inventory days as levers with a cost of capital attached, not as balances that happen to you. Ask of every working-capital number the question a founder cannot avoid asking: if the facility were withdrawn tomorrow, how long would this business remain liquid, and what would extend the runway. On a mandate, that is one of the first disciplines I establish, because a finance function that can answer it is a finance function the board can trust with the next decision.

Working capital stops being a number on a report the moment the money at risk is your own.

References

Office for National Statistics, Business Demography, UK: 2024 (published November 2025), business survival rates by birth cohort: ons.gov.uk

ING (THINK), With a Little Help From My Friends: the importance of CDMOs will continue to grow (20 January 2026), citing Pharma Advancement, share of pharmaceutical production outsourced to contract manufacturers rising from 34% (2014) to 49% (2023): think.ing.com

Lonza, press release, 1 May 2020, ten-year strategic manufacturing collaboration with Moderna: lonza.com